Page last updated: 2024-09-03

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and pirenzepine

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with pirenzepine in 6 studies

Compound Research Comparison

Studies
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)
Trials
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)
Recent Studies (post-2010)
(n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine)
Studies
(pirenzepine)
Trials
(pirenzepine)
Recent Studies (post-2010) (pirenzepine)
2145583,812587140

Protein Interaction Comparison

ProteinTaxonomyn(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine (IC50)pirenzepine (IC50)
Muscarinic acetylcholine receptor M2Homo sapiens (human)0.6891
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.5856
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)0.6134
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)0.6222
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)0.6227
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)0.6227
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.3406
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)0.6281
Muscarinic acetylcholine receptor M1Homo sapiens (human)0.0291
Muscarinic acetylcholine receptor M1Mus musculus (house mouse)0.75
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.9556
Muscarinic acetylcholine receptor M4Mus musculus (house mouse)0.75
Muscarinic acetylcholine receptor M5Mus musculus (house mouse)0.75
Muscarinic acetylcholine receptor M3Mus musculus (house mouse)0.75
Muscarinic acetylcholine receptor M2Mus musculus (house mouse)0.51

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bartoccini, F; Carminati, P; Castorina, M; Di Cesare, MA; Di Serio, S; Gallo, G; Ghirardi, O; Giorgi, F; Giorgi, L; Minetti, P; Piersanti, G; Tarzia, G; Tinti, MO1
Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X1
Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG1
Anzini, M; Brogi, S; Butini, S; Campiani, G; Cappelli, A; Caselli, G; Castriconi, F; Gemma, S; Giordani, A; Giorgi, G; Giuliani, G; Lanza, M; Letari, O; Makovec, F; Manini, M; Mennuni, L; Valenti, S1
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E1
Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E1

Other Studies

6 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and pirenzepine

ArticleYear
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
    Journal of medicinal chemistry, 2005, Nov-03, Volume: 48, Issue:22

    Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Models, Molecular; Motor Activity; Purines; Radioligand Assay; Rats; Rats, Inbred F344; Structure-Activity Relationship; Triazoles

2005
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
    Journal of medicinal chemistry, 2008, Jul-24, Volume: 51, Issue:14

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship

2008
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
    Journal of medicinal chemistry, 2008, Nov-27, Volume: 51, Issue:22

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship

2008
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
    European journal of medicinal chemistry, 2013, Volume: 63

    Topics: Animals; Area Under Curve; Humans; Intestinal Absorption; Ligands; Male; Metabolic Clearance Rate; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidinones; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin, 5-HT3; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship

2013
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
    Bioorganic & medicinal chemistry, 2016, Apr-15, Volume: 24, Issue:8

    Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine

2016
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
    Bioorganic & medicinal chemistry, 2017, 01-15, Volume: 25, Issue:2

    Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship

2017